abstract |
The solid dispersion is in an essentially amorphous form, dispersed in a solid matrix comprising (a) a pharmaceutically acceptable water-soluble polymer carrier and (b) a pharmaceutically acceptable surfactant. Kinase inhibitory compounds such as N- (4- {4-amino-7- [1- (2-hydroxyethyl) -1H-pyrazol-4-yl] thieno [3,2-c] pyridin-3-yl } Phenyl) -N ′-(3-fluorophenyl) urea. Methods for preparing such solid dispersions include dissolving the compound, polymer carrier and surfactant in a suitable solvent, and removing the solvent to include the polymer carrier and surfactant, in which Providing a solid matrix having a compound dispersed in a non-crystalline form. The solid dispersion is suitable for oral administration to a subject in need thereof for the treatment of cancer. |